Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval BLA Submission for TA-ERT is Now ...
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Based on FDA Feedback, Company Continues to Advance BLA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results